In this study, we compared the relative abilities of human thymidylate synthase (hTS) and Escherichia coli thymidylate synthase (eTS) expression to confer resistance to the cytotoxic effects of treatment with the TS inhibitor 5-fluorodeoxyuridine (FdUrd). G418-selected clones expressing either form of the protein were significantly more resistant than the lacZ-expressing clone, VALZ2, to FdUrd-induced cytotoxicity. Although eTS-expressing clones expressed 2-to 3-fold more TS protein than hTS-overexpressing clones, the representative eTS-expressing clone, VAEG8, and hTS-overexpressing clone, VAHGC, were equally sensitive to an FdUrd-induced loss of clonogenicity; in addition, a large fraction of either form of exogenously expressed TS appeared to be inactive in the intact cell. The clones differed, however, in their responses to leucovorin (LV). Although LV significantly enhanced FdUrd-induced TS inhibition, growth inhibition, and cytotoxicity in VAHGC cells, it had no effect on these parameters in VAEG8 cells. These results suggest that eTS may more efficiently confer resistance to FdUrd plus LV when expressed for the purposes of a "host protection" strategy in vivo.
O ne of the major limitations of cancer chemotherapy is that normal host tissues are often only slightly less sensitive to the cytotoxic effects of these drugs than are tumor cells. This problem is exacerbated by the fact that tumor cells frequently become more resistant during the course of drug treatment, whereas resistance does not normally arise in host tissues. With the development of techniques for selective expression of genes in vivo, however, it is now possible to envision gene therapy protocols in which drug resistance genes would be used to protect sensitive host tissues, thereby permitting the intensification of drug treatments to levels that would otherwise be intolerable. 1, 2 In one example of such a "host protection" strategy, Zhao et al 3 effectively protected mouse bone marrow cells in vivo from the cytotoxic effects of methotrexate by expressing a mutant dihydrofolate reductase gene in those cells. 3 Our previous studies on the actions of the fluoropyrimidines 5-fluorouracil (FUra) and 5-fluorodeoxyuridine (FdUrd) led us to consider how a host protection strategy might best be implemented in concert with these drugs. In many circumstances, the cytotoxic effects of FUra or FdUrd result from inhibition of the enzyme thymidylate synthase (TS). 4 This inhibition causes depletion of intracellular thymidine triphosphate pools and accumulation of deoxyuridine triphosphate pools, eventually leading to DNA synthesis inhibition, uracil misincorporation into DNA, DNA strand breaks, and cell death. [5] [6] [7] [8] Because elevated levels of TS in tumor cells have been linked to FdUrd resistance in both in vitro and in vivo studies, 9 -12 overexpression of this enzyme would appear to be an effective means of protecting normal tissues from FUra or FdUrd in vivo.
Although the choice of TS as the protein to express to induce resistance to fluoropyrimidines appears straightforward, what form of TS should be used in a host protection strategy may be less obvious. One concern is TS translational autoregulation. Human TS (hTS) protein is able to bind its own mRNA transcript and block the translation of new protein, creating a feedback loop that may limit the extent to which hTS can accumulate in human cells. 13, 14 Although translational autoregulation has also been observed for Escherichia coli TS (eTS) (E. Chu, unpublished observations), it is possible that this mechanism may not occur as efficiently when eTS is expressed in human cells. Thus, higher levels of TS protein (and therefore greater resistance) might accumulate from a given level of eTS mRNA expression, compared with the same level of hTS mRNA expression. As a first step in determining the most effective strategy for using TS expression to protect host tissues from fluoropyrimidine toxicity (and other agents that target TS), we have compared hTS and eTS with regard to their abilities to protect human VA13 cells from the effects of FdUrd treatment in vitro. Our results indicate that eTS does protect these cells more effectively than hTS, particularly when FdUrd is used with leucovorin (LV).
MATERIALS AND METHODS

Cell culture and drug solutions
VA13 cells were obtained from the American Type Culture Collection (Manassas, Va) and maintained in RPMI 1640 medium (Life Technologies, Gaithersburg, Md) supplemented with 10% fetal bovine sera (Life Technologies), 2 mM Lglutamine, and penicillin/streptomycin at 37°C in a 5% carbon dioxide atmosphere. VA13 is a nontumorigenic human lung fibroblast cell line derived by simian virus 40 transformation of WI38 cells. GPϩE86 and GPϩenvAM12 cells are ecotropic (E86) and amphotropic (AM12) retroviral producer cell lines grown under similar conditions in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% calf sera (Life Technologies) and 2 mM L-glutamine. 15, 16 FdUrd (Sigma, St. Louis, Mo) and LV (Sigma) were dissolved in doubledistilled water and stored at 4°C for up to 2 months. CH 2 FH 4 was generated by mixing FH 4 (Sigma) at a 10:1 molar ratio with formaldehyde in 100 mM KH 2 PO 4 (pH 7.2) and 50 mM ␤-mercaptoethanol as described previously. 17 
Retroviral constructs
The pLNCX.lacz construct was provided by Dr. Eric Radany, (University of Michigan, Ann Arbor, Mich). pLNCX.hTS was provided by Drs. Kevin McDonagh and Philip Stetson (University of Michigan). For pLNCX.eTS, the eTS gene was amplified by polymerase chain reaction using pBTAH 18 as a template as well as primers that added EcoRI and XhoI sites to the 5Ј end of the gene and EcoRI and ClaI sites to the 3Ј end of the gene. The modified eTS fragment was then ligated into pUC18 (Life Technologies) at the EcoRI cloning site. The resultant construct, pUC.eTS, was digested with XhoI and ClaI to isolate the eTS gene, which was then ligated into the pLNCX retroviral vector. Expression of lacZ, hTS, or eTS in each vector is driven by the cytomegalovirus promoter. Expression of the neomycin resistance gene in each vector is driven by the pLNCX long terminal repeat promoter.
Retroviral-mediated transduction of cells for expression of ␤-galactosidase, hTS, or eTS
GPϩE86 cells were transfected with pLNCX.lacZ, pLNCX.hTS, or pLNCX.eTS using N- [1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethylammonium methylsulfate transfection reagent (Boehringer Mannheim, Indianapolis, Ind). G418-resistant clones were screened by either Western blot analysis (hTS and eTS) or by 5-bromo-4-chloro-3-indolyl ␤-D-galactoside staining (lacZ) for expression of the appropriate protein. Retroviral supernatants from selected clones were then used to infect GPϩenvAM12 cells in the presence of 8 g/mL polybrene. TS-expressing AM12 clones were selected with 10 nM FdUrd rather than G418. Conditioned media from AM12 clones expressing high levels of the appropriate proteins were then used to infect VA13 cells as described above. All VA13 clones were selected with 0.4 mg/mL G418.
Extracted TS catalytic activity assay and 3 H-5-fluoro-2Ј-deoxyuridine monophosphate (FdUMP) titration Cell lysates were prepared as described previously. 11 Briefly, exponentially growing cells treated with FdUrd for 0, 2, 6, or 24 hours were washed and harvested in ice-cold phosphatebuffered saline. Cells were then resuspended in ice-cold 0.1 M KH 2 PO 4 (pH 7.2) sonicated on ice using three 3-second bursts, and centrifuged at 10,000 ϫ g for 30 minutes at 4°C. Lysates were then assayed for either TS catalytic activity or 3 HFdUMP titratable protein as described previously.
11
For TS catalytic activity measurements, 30 L of cell lysate was incubated in a 50-L total volume of 50 mM tris(hydroxymethyl)aminomethane (pH 7.5), 5 mM MgCl 2 , 50 mM NaF, 1 mM CH 2 FH 4 , and 0.1 mM deoxyuridine monophosphate (dUMP) (10:1 ratio cold dUMP: [5- 3 H]dUMP (1 mCi/ mL; 20.2 Ci/mmol; Moravek Biochemicals, Brea, Calif)) at 37°C for 0, 10, 20, or 40 minutes. Reactions were stopped by the addition of 100 L of 15% activated charcoal/4% perchloric acid solution. Samples were then centrifuged for 4 minutes at 10,000 rpm. The amount of radioactivity in a 50-L aliquot of each reaction supernatant was determined by liquid scintillation counting to calculate the fraction of 3 
In situ TS catalytic activity assay
This assay is slightly modified from a previously published method. 20 Cells were plated at a density of 6000 cells/cm 2 in 24-well dishes. After 3 days, cells were treated with FdUrd for 2 hours and subsequently loaded with 0.5 mL of 12 nM [5- 3 H]2Ј-deoxycytidine (dCyd) (1.0 mCi/mL; 25.8 Ci/mmol; Moravek Biochemicals) in the continued presence of FdUrd for 4 hours as described previously. A total of 2 mL of ice-cold 0.2 N trichloroacetic acid/5% activated charcoal solution was added to each well to stop the reaction. To determine the fraction of 3 H released from [5- 3 H]dCyd, 1 mL of each reaction was centrifuged at 10,000 ϫ g for 5 minutes, and the amount of radioactivity in a 0.5-mL aliquot of supernatant was measured with liquid scintillation counting. Preliminary studies using either an excess of substrate (120 nM dCyd) or earlier timepoints (15, 30 
Growth inhibition and clonogenic assay
For the determination of FdUrd-induced growth inhibition, cells were plated at a density of 6000 cells/cm 2 in 24-well dishes. After 2 days, cells were treated with FdUrd in medium supplemented with 10% dialyzed fetal bovine sera. After 48 hours, cells were trypsinized and counted with a Model Z1 Coulter Counter (Coulter Electronics, Miami Lake, Fla).
For the clonogenic assay, cells were plated at a density of 1000 cells/cm 2 and allowed to recover for 3 days before treatment with FdUrd. For samples undergoing 48 hours of drug treatment, medium was replenished after 24 hours. Cells were then trypsinized and replated in medium supplemented with 10 M thymidine to restore thymidine triphosphate levels. After 12 days, surviving colonies (Ͼ50 cells) were fixed with a 3:1 methanol:acetic acid solution and stained with trypan blue. The surviving fraction was calculated as the plating efficiency for the drug-treated cells divided by the plating efficiency for the corresponding non-drug-treated cells. Control plating efficiencies ranged from 0.08 to 0.12 for VALZ2 and VAHGC cells and from 0.04 to 0.06 for VAEG8 cells.
High-performance liquid chromatography (HPLC) analysis of FdUMP levels after treatment with FdUrd
FdUrd nucleotides were extracted from exponentially growing cells after treatment with 1 M FdUrd (10:1 ratio of cold FdUrd: [6- 3 H]-FdUrd (1.0 mCi/mL; 19 Ci/mmol; Moravek Biochemicals) for 2 hours as described previously. 21 Briefly, cells were washed in ice-cold phosphate-buffered saline and ϳ10 6 cells were lysed in 40 L of 1 M perchloric acid in 0.1 M ammonium formate buffer (pH 2). Cell lysates were incubated on ice for 5 minutes before centrifuging at 1600 ϫ g for 5 minutes. The supernatant (acid soluble fraction) was carefully collected, neutralized to a pH of 7 with 2 M KOH, and stored at Ϫ20°C until HPLC analysis.
HPLC analysis was performed on a 4.6 ϫ 250 mm Microsorb C18 reverse phase column (Rainin Instrument Company, Woburn, Mass). The mobile phase was composed of 97.5% buffer (0.1 mM tetrabutylammonium dihydrogen phosphate (Sigma), 20 mM KH 2 PO 4 (pH 5.9)) and 2.5% methanol with a flow rate of 0.5 mL/minute. 22 Before injection, FUra, FdUrd, and FdUMP standards were added to each sample to monitor column performance and determine elution times: FUra eluted at 11 minutes, FdUrd at 32 minutes, and FdUMP at 44 minutes. Samples were collected in 2-minute fractions, and the amount of radioactivity in each fraction was determined by liquid scintillation counting. Typically, Ͼ90% of the recovered radioactivity co-eluted with the FdUMP peak. Data are presented as picomoles of free FdUMP per 10 6 cells.
RESULTS
Levels of eTS or hTS expression, and sensitivity to
FdUrd-induced growth inhibition, in VA13 clones selected for resistance to G418 Figure 1 shows the levels of TS catalytic activity observed in cellular extracts from clonal cell lines derived by infection of VA13 cells with either pLNCX.hTS or pLNCX.eTS retrovirus, followed by selection with G418. The average value for activity in eTS-expressing clones (1867 Ϯ 237 U) was significantly higher than for hTSexpressing clones (933 Ϯ 156 U) (P ϭ .014, MannWhitney U test), and the activities of both types of clones were 10-to 50-fold higher the activity measured in either the lacZ control line, VALZ2 (51.8 U), or the parental VA13 line (40.4 U). Table 1 relates extracted TS catalytic activity to TS protein content for four clones expressing either hTS (VAHGK and VAHGC) or eTS (VAEG6 and VAEG8). Within this group, there was a significant correlation between extracted catalytic activity and TS protein content (r 2 ϭ 0.849, P ϭ .039, one-tailed test).
In general, VA13 clones expressing eTS were also (Fig 1) , although this difference did not quite reach statistical significance (P ϭ .051, Mann-Whitney U test). There also appeared to be a difference in the relationship between extracted TS catalytic activity and resistance to FdUrd-induced growth inhibition between the two types of clones. In the hTS-expressing clones, although the level of extracted TS activity varied from 433 to 1386 U, the 50% inhibitory concentration (IC 50 ) values for FdUrd-induced growth inhibition in these clones were all ϳ80 nM, suggesting that a plateau for FdUrd resistance had been reached; in contrast, in the eTS-expressing clones, we observed IC 50 values for FdUrd-induced growth inhibition that reached as high as 298 nM, and which generally correlated with extracted TS activity. These data suggest that there may be qualitative differences in the effects of either hTS or eTS expression in human cells.
Concentration dependence of FdUrd-mediated inhibition of total TS activity, in situ TS activity, proliferation, and clonogenicity in normal and TSoverexpressing cells Because the data in Figure 1 suggested that hTS and eTS differ in their ability to confer resistance to FdUrdinduced growth inhibition, we characterized the concentration dependence of inhibition of hTS and eTS catalytic activity by FdUrd. It was reported previously that inhibition of intracellular TS activity did not necessarily correspond to inhibition of total extractable TS activity. 23 Therefore, we measured both total extracted TS activity (as in Fig 1) and in situ TS activity in intact cells, after exposure to various concentrations of FdUrd. In addition, we measured the loss of clonogenicity caused by these treatments.
In VALZ2 control cells (Fig 2) , we found that inhibition of in situ TS activity by FdUrd diverged from inhibition of total TS activity at 0.01 nM, but that the two endpoints coincided quite closely (relative to their values in untreated cells) at higher drug concentrations. The log-concentration/effect curves for inhibition of in situ TS activity and growth inhibition were both well fitted to a sigmoidal function, with calculated IC 50 values of 0.068 nM and 0.71 nM, respectively. Loss of clonogenicity did not occur until much higher concentrations (30 -100 nM, depending upon the length of drug treatment) were used.
In the hTS-overexpressing cells chosen for these studies (clone VAHGC, Fig 3) we also observed sigmoidal curves for in situ TS inhibition and growth inhibition. As expected, these curves were shifted rightward compared with their VALZ2 counterparts (IC 50 ϭ 8.3 nM for in situ TS inhibition, 87 nM for growth inhibition), as was the threshold concentration for loss of clonogenicity (Ͼ300 nM). Despite the fact that total extracted TS activity in VAHGC cells was ϳ20-fold higher than in VALZ2 cells, the values for in situ TS activity in these two cell lines, in the absence of FdUrd, were almost identical (ϳ5 U). As was the case in VALZ2 cells, inhibition of extracted TS activity occurred at a lower concentration than inhibition of in situ activity. However, unlike VALZ2 cells, high concentrations of FdUrd were unable to completely eliminate extracted TS activity in VAHGC cells. As a result, in VAHGC cells that were completely growth inhibited and experiencing significant loss of clonogenicity (1 M FdUrd), extractable TS activity was still present at a level (220 U) several times higher than that found in VALZ2 cells in the absence of drug (60 U).
The profile of response of eTS-expressing cells (clone VAEG8, Fig 4) was similar to that of VAHGC cells in some respects, including IC 50 for in situ TS inhibition (11.3 nM) and growth inhibition (202 nM), and threshold concentration for loss of clonogenicity (Ͼ300 nM). Extractable TS activity was much more resistant to FdUrd inhibition in VAEG8 cells than in VAHGC cells, however, with ϳ1200 U detectable after treatment of cells with FdUrd concentrations ranging from 10 nM to 10 M. In view of the finding that the level of extracted TS activity in VAEG8 cells was unchanged over the same range of drug concentrations in which growth inhibition varied from minimal to complete, and in which loss of clonogenicity ranged from 0 to 3 log units, we conclude that measurement of extracted TS activity is not predictive of biological response to FdUrd treatment in this system.
Disposition of FdUrd in control and TS-overexpressing cells
One possible explanation for the failure of high concentrations of FdUrd to completely inhibit total extractable TS activity in VAHGC and VAEG8 cells is that thymidine kinase activity in these cells is inadequate to provide enough FdUMP to bind the excess TS protein.
After treatment of cells with 1 M FdUrd, however, considerable levels of free FdUMP were present in each of the three clones examined (Fig 5) . Therefore, inadequate anabolism of FdUrd to FdUMP cannot account for the residual TS activity extracted from VAHGC or VAEG8 cells after exposure to high levels of FdUrd.
Effects of LV on FdUrd-induced TS inhibition and cytotoxicity in VAHGC and VAEG8 cells A second possible explanation for residual extracted TS activity after FdUrd treatment is that intracellular folate levels are insufficient for complete ternary complex formation of the excess TS protein. Therefore, we subsequently examined the impact of adding reduced folate (LV) to the FdUrd treatment. Although 100 M LV had no effect on FdUrd-induced growth inhibition in VALZ2 cells, it significantly decreased the IC 50 for FdUrd-induced growth inhibition in all four hTS-expressing clones examined, from 2.6-to 17-fold (Table 2) . LV also enhanced the inhibition of extractable TS activity in both of the hTS clones in which this endpoint was measured. In contrast, LV had no effect either on FdUrd-induced growth inhibition or on the inhibition of extractable TS activity in either of the eTS clones tested. The difference in response to LV between hTS and eTS clones was also reflected in terms of cytotoxicity (Fig 6) . Although the addition of LV increased the FdUrdinduced loss of clonogenicity in VAHGC cells by as much as 1 log unit, the response of VAEG8 cells under the same conditions was not affected by LV. Therefore, inadequate levels of endogenous reduced folates can explain much of the residual extracted TS activity after FdUrd treatment in the hTS-overexpressing cells, but not in the eTS-expressing cells.
DISCUSSION
We were originally motivated to compare the effects of hTS versus eTS expression because of the possibility that eTS might be more efficiently produced in human cells, and might therefore be a more effective means of protecting host cells from TS inhibitors. Although this quantitative difference did indeed materialize, as shown by Figure 1 and Table 1 , the more surprising and interesting results of this study concern the qualitative differences between eTS and hTS in the context of human cells.
The data in Figures 2-4 describe the profiles for FdUrd-induced TS inhibition, growth inhibition, and cytotoxicity for the three clones VALZ2, VAHGC, and VAEG8. Although extracted TS catalytic activity levels varied widely among the three clones (from 60 to 2700 U), they all had similar in situ TS activity levels. Danenberg and Danenberg 23 previously described a FdUrdresistant human cell line with in situ TS catalytic activity similar to that observed in the control cell line, even though the resistant cells expressed higher levels of TS protein (as determined by 3 H-FdUMP titration). In addition, Ayusawa et al 24 found that in mouse TS Ϫ cells containing high levels of hTS protein, TS activity levels were actually slightly lower than the level of activity in wild-type mouse cells. Based on these observations, both groups proposed that the majority of the amplified or exogenously expressed TS is inactive in the intact cell. This hypothesis is consistent with our data. Although the extracted TS catalytic activity assay and 3 H-FdUMP titration assay confirm that there is much more TS protein in the VAHGC and VAEG8 cells, and that this Figure 6 . The effects of LV on FdUrd-induced cytotoxicity in VAHGC and VAEG8 cells. VAHGC and VAEG8 cells were assayed for loss of clonogenicity after treatment with 300 nM FdUrd for either 24 or 48 hours, in the presence (FdUrd/LV) or absence (FdUrd alone) of 100 M LV. LV significantly enhanced FdUrd-induced cytotoxicity in VAHGC cells ‫,ء(‬ P ϭ .0047; ‫,ءء‬ P ϭ .0007; Student's t test), but it had no effect on the sensitivity of VAEG8 cells to FdUrd. Data are presented as the mean Ϯ SE of three independent experiments. protein is functional, the in situ TS assay data suggest that, in the intact cell, much of this protein is inactive. The hypothesis that much of the excess TS in VAHGC and VAEG8 cells is inactive in the intact cell is further supported by the relationship between FdUrd-induced growth inhibition and TS inhibition in both clones. The curves for drug-induced growth inhibition and in situ TS inhibition are roughly coincident in each clone examined (Figs 2-4) . In contrast, when we examined extracted TS catalytic activity after treatment with FdUrd, we found that substantial levels of uninhibited TS were present in both VAHGC and VAEG8 cells at drug concentrations that completely inhibited growth and induced a significant loss of clonogenicity. FdUrd-induced cytotoxicity at the higher concentrations does not appear to be due to lesions other than TS inhibition, as the cytotoxic effects of treatment with 3 M FdUrd for 48 hours were completely prevented by cotreatment with 10 M thymidine (data not shown). These results further support the hypothesis that much of the excess TS in VAHGC and VAEG8 cells is inactive, or unable to sustain growth, in the intact cell.
Another point brought out by the data presented in Figures 2-4 is the disparity between the concentration of drug required for FdUrd-induced TS and growth inhibition and the concentration required for drug-induced loss of clonogenicity. Although the requirement for almost complete in situ TS inhibition to induce FdUrdinduced growth inhibition has been described previously, 25 many studies use drug-induced growth inhibition as the endpoint for determining relative sensitivity to FdUrd. Our results indicate that these studies may underestimate the amount of drug required for a cytotoxic effect. In each clone, concentrations of FdUrd that induced Ͼ95% in situ TS inhibition and growth inhibition did not induce any loss of clonogenicity, even when the length of drug treatment was extended to 72 hours (data not shown). In addition, the observation that VAEG8 cells are 3-fold more resistant than VAHGC cells to FdUrd-induced growth inhibition, but equally sensitive to FdUrd-induced loss of clonogenicity, suggests that growth inhibition may not be the best parameter for determining relative sensitivity to FdUrd-induced cytotoxicity, at least in this cell line.
It is unclear why we are unable to completely inhibit extractable TS activity in the VAHGC and VAEG8 cells. One possible explanation is that thymidine kinase activity in these cells is inadequate to provide enough FdUMP to bind the high levels of TS protein present. However, we found considerable levels of free intracellular FdUMP in all three clones treated with 1 M FdUrd for 2, 6, or 24 hours (Fig 5) . In addition, if the amount of TS protein present in VAHGC and VAEG8 cells (on a per cell basis) is estimated and compared with the amount of free FdUMP present, FdUMP is present in an excess of TS protein. Therefore, FdUMP does not appear to be a limiting factor for TS inhibition in VAHGC or VAEG8 cells after exposure to high levels of FdUrd.
One clear difference between the eTS-and hTSexpressing clones is in their response to the addition of LV to FdUrd treatments (Table 2 and Fig 6) . The difference between VAHGC and VAEG8 cells with regard to the effect of LV was unexpected in view of earlier reports that found that eTS and hTS have similar K m values for 5,10-methylene tetrahydrofolate in the normal catalytic reaction. 26 -29 In addition, studies using purified forms of either hTS or bacterial TS reported that the presence of high levels of reduced folate cofactor enhanced FdUMP binding to TS by slowing the rate of dissociation of the ternary complex. 30, 31 Therefore, the potentiation of FdUrd toxicity in VAHGC cells by LV can be explained by the enhanced binding of FdUMP to TS in those cells. This hypothesis is supported by the enhanced inhibition of extractable TS catalytic activity in VAHGC cell lysates by LV (Table 2) . What is more difficult to explain is the lack of effect of LV in VAEG8 cells. Presumably, LV would still be able to enhance FdUMP binding to endogenous TS in those cells. FdUrd-induced inhibition of in situ TS activity, however, was not affected by LV in VAEG8 cells (data not shown). In addition, inhibition of extractable TS activity was not affected in VAEG8 cells, suggesting that FdUMP binding to eTS (which presumably accounts for most of the extractable TS activity in VAEG8 cell lysates) is not enhanced by enriching the reduced folate pool. It appears, therefore, that although eTS, FdUMP, and reduced folate (LV) are present in excess in VAEG8 cells treated with high concentrations of FdUrd, the inhibitory ternary complex is not forming efficiently in the intact cell, perhaps due to intracellular localization of one of these factors.
Overall, there are several observations from these studies that may have an impact on a fluoropyrimidine host protection strategy. First, despite the proposed autoregulation of hTS protein levels in "normal" cells, 13, 14 we were able to induce sufficiently high levels of hTS protein to confer resistance to the TS inhibitor FdUrd. Although TS gene amplification has been observed in several cell lines and tumors in response to drug treatment, 9 -11 and initial studies have examined the protective effects of retrovirally induced hTS overexpression in murine retroviral producer cells, 32 this is the first report of retrovirally induced overexpression of hTS in human cells. In addition, because the hTSoverexpressing clones were selected with G418 rather than a TS inhibitor, it is reasonable to assume that any observed drug resistance is due entirely to TS overexpression and is not mediated in part by additional drug resistance mechanisms, such as down-regulation of thymidine kinase (for FdUrd).
The similar sensitivities of VAHGC and VAEG8 cells to FdUrd-induced loss of clonogenicity suggested that hTS would be just as effective as eTS at conferring drug resistance to FdUrd in vivo, with the advantage of avoiding the potential immunological responses induced by eTS expression in human tissues. In cells treated with FdUrd plus LV, however, eTS was significantly more effective than hTS at conferring drug resistance. As FUra is now frequently used in conjunction with LV, these results suggest that eTS may be the TS gene of choice for a host protection strategy designed in concert with those drugs.
In addition to host protection strategies, TS could be used as a selection marker for a metabolic gene of interest. Despite recent advances in in vivo gene delivery, transduction efficiency remains a limiting factor for the success of treatment. Construction of vectors with TS in addition to a therapeutic gene would allow for in vivo selection of cells expressing the therapeutic gene, maximizing transduction efficiency and therapeutic potential.
